JMP Securities analyst Reni Benjamin initiated coverage of Inhibrx with a Market Perform rating without a price target following Sanofi’s acquisition of INBRX-101 and subsequent spinout of the remaining assets. The analyst believes the company is well capitalized to develop its hexavalent OR40 agonist and DR5 agonist but sees the shares as fairly valued.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBX: